FDA Approves New Esophageal Cancer Drug FDA Approves New Esophageal Cancer Drug
The checkpoint inhibitor is approved for second-line treatment of patients with esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD-L1 inhibitor.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Esophagus Cancer | Hematology | Skin Cancer | Squamous Cell Carcinoma